Literature DB >> 26374300

Prognostic value of forced expiratory volume in 1 second/forced vital capacity in idiopathic pulmonary fibrosis.

Osamu Nishiyama1, Ryo Yamazaki2, Akiko Sano2, Toshiyuki Yamagata2, Hiroyuki Sano2, Takashi Iwanaga2, Yuji Higashimoto2, Hiroaki Kume2, Yuji Tohda2.   

Abstract

Emphysema on high-resolution computed tomography of the chest is the recent focus in the general practice in idiopathic pulmonary fibrosis (IPF). However, adequate attention has not been paid to obstructive disorder. Therefore, we retrospectively evaluated the association between the degree of airway obstruction and longevity in IPF subjects, with a hypothesis that lower forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) has an impact on prognosis. One hundred and fourteen consecutive IPF subjects who had been diagnosed with IPF and had undergone evaluation including pulmonary function test from January 2008 to May 2013 were included in the study. The relationship between baseline data and survival was examined. FEV1/FVC was widely distributed, ranging from 48.6% to 100%. On both univariate and multivariate Cox's regression analyses, lower FEV1/FVC was significantly associated with better survival (hazard ratio of 1.07 and 1.04 and 95% confidential interval of 1.03-1.10 and 1.01-1.08, respectively). Even on analysis with backward selection, FEV1/FVC remained a significant prognostic factor. FEV1/FVC is widely distributed and negatively predicts survival in IPF. A FEV1/FVC should be assessed in "real-world" general practice. Also, the effect of smoking on the clinical course of IPF should be investigated further.
© The Author(s) 2015.

Entities:  

Keywords:  FEV1/FVC; idiopathic pulmonary fibrosis; interstitial; lung disease; obstructive; prognosis

Mesh:

Year:  2015        PMID: 26374300      PMCID: PMC5720194          DOI: 10.1177/1479972315603714

Source DB:  PubMed          Journal:  Chron Respir Dis        ISSN: 1479-9723            Impact factor:   2.444


  29 in total

1.  Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.

Authors:  Roland M du Bois; Derek Weycker; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Alex Kartashov; Lisa Lancaster; Paul W Noble; Ganesh Raghu; Steven A Sahn; Javier Szwarcberg; Michiel Thomeer; Dominique Valeyre; Talmadge E King
Journal:  Am J Respir Crit Care Med       Date:  2011-08-15       Impact factor: 21.405

2.  The effect of emphysema on lung function and survival in patients with idiopathic pulmonary fibrosis.

Authors:  Kazuyoshi Kurashima; Noboru Takayanagi; Noriko Tsuchiya; Tetsu Kanauchi; Miyuki Ueda; Toshiko Hoshi; Yosuke Miyahara; Yutaka Sugita
Journal:  Respirology       Date:  2010-06-04       Impact factor: 6.424

3.  Body mass index and mortality in patients with idiopathic pulmonary fibrosis.

Authors:  Mazen Alakhras; Paul A Decker; Hassan F Nadrous; Maria Collazo-Clavell; Jay H Ryu
Journal:  Chest       Date:  2007-03-30       Impact factor: 9.410

4.  Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model.

Authors:  T E King; J A Tooze; M I Schwarz; K R Brown; R M Cherniack
Journal:  Am J Respir Crit Care Med       Date:  2001-10-01       Impact factor: 21.405

5.  The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis.

Authors:  Charlene D Fell; Lyrica Xiaohong Liu; Caroline Motika; Ella A Kazerooni; Barry H Gross; William D Travis; Thomas V Colby; Susan Murray; Galen B Toews; Fernando J Martinez; Kevin R Flaherty
Journal:  Am J Respir Crit Care Med       Date:  2008-12-12       Impact factor: 21.405

6.  Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia.

Authors:  Kevin R Flaherty; Jeanette A Mumford; Susan Murray; Ella A Kazerooni; Barry H Gross; Thomas V Colby; William D Travis; Andrew Flint; Galen B Toews; Joseph P Lynch; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2003-05-28       Impact factor: 21.405

7.  Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.

Authors:  Christopher J Ryerson; Thomas Hartman; Brett M Elicker; Brett Ley; Joyce S Lee; Marta Abbritti; Kirk D Jones; Talmadge E King; Jay Ryu; Harold R Collard
Journal:  Chest       Date:  2013-07       Impact factor: 9.410

8.  Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome.

Authors:  V Cottin; J Le Pavec; G Prévot; H Mal; M Humbert; G Simonneau; J-F Cordier
Journal:  Eur Respir J       Date:  2009-07-30       Impact factor: 16.671

9.  Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends.

Authors:  Panagiota I Latsi; Roland M du Bois; Andrew G Nicholson; Thomas V Colby; Danai Bisirtzoglou; Ageliki Nikolakopoulou; Srihari Veeraraghavan; David M Hansell; Athol U Wells
Journal:  Am J Respir Crit Care Med       Date:  2003-06-05       Impact factor: 21.405

10.  Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis.

Authors:  Takanori Akagi; Takemasa Matsumoto; Taishi Harada; Makoto Tanaka; Takashige Kuraki; Masaki Fujita; Kentaro Watanabe
Journal:  Respir Med       Date:  2009-02-28       Impact factor: 3.415

View more
  2 in total

1.  Obstructive lung function decline and IPF: The dark face of the moon.

Authors:  Mauro Carone; Francesco G Salerno; Antonio M Esquinas
Journal:  Chron Respir Dis       Date:  2016-02-01       Impact factor: 2.444

2.  Obstructive lung function in idiopathic pulmonary fibrosis.

Authors:  Osamu Nishiyama; Yuji Tohda
Journal:  Chron Respir Dis       Date:  2016-02-09       Impact factor: 2.444

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.